In addition to the increased production of pro-inflammatory cytokines via OV, the inhibition of anti-inflammatory cytokines and their effects on CAR T-cell therapy were evaluated by Y. Li et al. They examined the OAds expressing soluble receptor of TGF-β (an important immunomodulatory factor that inhibits anti-tumor immunity in TME) (rAd.sT) in a triple-negative Breast cancer xenograft mouse model. The gene discussed is TGFB1; the disease is neoplasm.